Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism
Authors:
Open Access
- 20 June 2017
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 158 (9) , 2722-2740
Abstract
Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed results in osteoporosis patients. Toward the goal of enhancing the efficacy of these regimens, we tested their utility in combination with loss of the transcription factor Nmp4 because disabling this gene amplifies PTH-induced increases in trabecular bone in mice by boosting osteoblast secretory activity. We addressed whether combining a sustained anabolic response with an anticatabolic results in superior bone acquisition compared with PTH monotherapy. Additionally, we inquired whether Nmp4 interferes with anticatabolic efficacy. Wild-type and Nmp4−/− mice were ovariectomized at 12 weeks of age, followed by therapy regimens, administered from 16 to 24 weeks, and included individually or combined PTH, alendronate (ALN), zoledronate (ZOL), and raloxifene (RAL). Anabolic therapeutic efficacy generally corresponded with PTH + RAL = PTH + ZOL > PTH + ALN = PTH > vehicle control. Loss of Nmp4 enhanced femoral trabecular bone increases under PTH + RAL and PTH + ZOL. RAL and ZOL promoted bone restoration, but unexpectedly, loss of Nmp4 boosted RAL-induced increases in femoral trabecular bone. The combination of PTH, RAL, and loss of Nmp4 significantly increased bone marrow osteoprogenitor number, but did not affect adipogenesis or osteoclastogenesis. RAL, but not ZOL, increased osteoprogenitors in both genotypes. Nmp4 status did not influence bone serum marker responses to treatments, but Nmp4−/− mice as a group showed elevated levels of the bone formation marker osteocalcin. We conclude that the heightened osteoanabolism of the Nmp4−/− skeleton enhances the effectiveness of diverse osteoporosis treatments, in part by increasing hyperanabolic osteoprogenitors. Nmp4 provides a promising target pathway for identifying barriers to pharmacologically induced bone formation.Keywords
This publication has 74 references indexed in Scilit:
- Combination therapy with risedronate and teriparatide in male osteoporosisEndocrine, 2012
- Differing effects of PTH 1–34, PTH 1–84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCTJournal of Bone and Mineral Research, 2012
- Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Nmp4/CIZ inhibits mechanically induced β‐catenin signaling activity in osteoblastsJournal of Cellular Physiology, 2010
- High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical PropertiesClinical Cancer Research, 2009
- Inhibiting the Inhibitor: A New Route to Bone AnabolismJournal of Bone and Mineral Research, 2009
- Osteoblast expression of an engineered G s -coupled receptor dramatically increases bone massProceedings of the National Academy of Sciences, 2008
- Comparative effects of 17β-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized miceOsteoporosis International, 2007
- Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular OsteoblastsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Anabolic Actions of Parathyroid Hormone on Bone*Endocrine Reviews, 1993